Special Edition 2015: Insights into Inhaled ABX Scheduling
e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Special Edition 2015)
Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.
After participating in this activity, the participant will demonstrate the ability to:
- Review the history of the current approved regimen for inhaled antibiotics for the treatment of airways infection in patients with cystic fibrosis.
- Identify the perceived inadequacies of inhaled antibiotics and current practice patterns in patients with cystic fibrosis.
- Evaluate the findings of the recently completed trial investigating continuous alternating inhaled antibiotic therapy for patients with cystic fibrosis.
Dr. Patrick Flume reports that he served as a consultant for Novartis, Vertex Pharmaceuticals, Inc, and Pharmaxis Limited. In addition he has received grant and research support from Novartis, Vertex Pharmaceuticals, Inc, Pharmaxis Limited, Boehringer Ingelheim Pharmaceuticals, Savara Pharma, and KaloBios.
Dr. Patrick Flume reports that the activity will not contain any discussion of off-label or unapproved drugs or products.
- 1.00 ANCC
- 1.00 Attendance